Astrazeneca (NYSE:AZN) Shares Gap Up – Should You Buy?

Astrazeneca Plc (NYSE:AZN) gapped up before the market opened on Friday . The stock had previously closed at $183.40, but opened at $190.88. Astrazeneca shares last traded at $190.3450, with a volume of 1,026,481 shares trading hands.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of “Moderate Buy,” which supports the stock’s upside but does not by itself explain today’s move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc (NYSE:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

Analysts Set New Price Targets

AZN has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. HSBC reiterated a “buy” rating and issued a $108.00 target price on shares of Astrazeneca in a report on Wednesday, December 10th. Weiss Ratings started coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Finally, Morgan Stanley restated an “overweight” rating and set a $103.00 price target on shares of Astrazeneca in a report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Stock Up 2.8%

The stock has a market capitalization of $292.45 billion, a P/E ratio of 28.79, a price-to-earnings-growth ratio of 1.42 and a beta of 0.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72.

Astrazeneca Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a dividend of $1.595 per share. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is presently 66.26%.

Hedge Funds Weigh In On Astrazeneca

Large investors have recently made changes to their positions in the business. IHT Wealth Management LLC grew its position in Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after purchasing an additional 54 shares in the last quarter. Visionary Wealth Advisors lifted its position in Astrazeneca by 1.5% in the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares in the last quarter. Vista Investment Management lifted its position in Astrazeneca by 0.3% in the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after buying an additional 60 shares in the last quarter. Kestra Investment Management LLC boosted its stake in shares of Astrazeneca by 1.9% during the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after buying an additional 63 shares during the period. Finally, Luken Investment Analytics LLC boosted its stake in shares of Astrazeneca by 4.3% during the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after buying an additional 64 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.